We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

89 hedge funds and large institutions have $133M invested in Concert Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less capital invested

Capital invested by funds: $133M → $133M (-$15.6K)

1.02% less ownership

Funds ownership: 59.16% → 58.14% (-1%)

5% less funds holding

Funds holding: 94 → 89 (-5)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

Holders
89
Holders Change
-5
Holders Change %
-5.32%
% of All Funds
2.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
33
Reduced
23
Closed
17
Calls
$110K
Puts
–
Net Calls
+$110K
Net Calls Change
-$30K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$4.92M
2
ISL
Ingalls & Snyder LLC
New York
+$1.59M
3
Millennium Management
Millennium Management
New York
+$1.06M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.04M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.19M
2
BFA
BlackRock Fund Advisors
California
-$1.95M
3
SIM
Spark Investment Management
New York
-$1.81M
4
SAM
Senzar Asset Management
New York
-$1.57M
5
BBA
Baker Bros. Advisors
New York
-$1.5M

CNCE Hedge Fund Activity: Q4 2016 in Review

89 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2016, worth a combined $133M — down 0.01% from $133M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CNCE and 14 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 33 added.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $4.92M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.19M sold.

  • 89 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2016, down from 94 in Q3 2016.
  • Funds reported $133M of Concert Pharmaceuticals, Inc. stock for Q4 2016, down 0.01% quarter-over-quarter.
  • 14 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2016 and 17 closed out, a net change of -3 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2016 was Cormorant Asset Management, an estimated $4.92M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2016 was Point72 Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2016.